

## 1992 INDEX

### A

- Abdomen: carcinomatosis with normal ovaries, Mar./Apr. 117
- Addiction: fears of, with pain of cancer therapy, Nov./Dec. 349
- Adenocarcinoma: of rectum, invasion and metastases, Sept./Oct. 286
- Adenoma
  - colorectal, progression carcinoma in situ, molecular events in, Sept./Oct. 275-280
  - development in transformation of colorectal carcinoma, Sept./Oct. 272-273
- Adenomatous polyposis syndrome: and APC gene, Sept./Oct. 273-274
- Adriamycin: in ovarian cancer, Mar./Apr. 93
- Age: in ovarian cancer prognosis, Mar./Apr. 82
- Analgesia: spinal, in cancer pain control, Nov./Dec. 360-364
- Analgesics
  - coanalgesics (see Coanalgesics)
  - opioid (see Opioid analgesics)
- Anticonvulsants: and pain of cancer, Nov./Dec. 349-352
- Antidepressants: in pain of cancer, Nov./Dec. 349-352
- Antiestrogens
  - in breast cancer prevention, May/June 164
  - in breast cancer treatment, May/June 164
  - effects in long-term tamoxifen, May/June 154-155
  - pure, May/June 150-151
  - strategy with, overall, May/June 163-164
- Antigen, carcinoembryonic (see Carcinoembryonic antigen)
- Antiinflammatory drugs: nonsteroidal, in pain of cancer, Nov./Dec. 349-352

- APC gene: and polyposis syndrome, familial adenomatous, Sept./Oct. 273-274
- Atherosclerosis: after tamoxifen, May/June 154-155

### B

- Basement membrane
  - in colorectal carcinoma prognosis, Sept./Oct. 286-287
  - receptors for attachment to, in colorectal carcinoma, Sept./Oct. 290-294
- Behavioral therapy: cognitive, and pain of cancer, Nov./Dec. 353
- BFU-E, July/Aug. 185
- Biology of colorectal carcinoma (see under Colorectal carcinoma)
- Biopsy: in ovarian cancer, Jan./Feb. 37
- Breast
  - cancer (see below)
  - carcinoma
    - dimethylbenzanthracene causing (in rat), May/June 139-140
    - N-nitrosomethylurea causing (in rat), May/June 140
- Breast cancer
  - chemotherapy, combination, adjuvant, May/June 142
  - development of, May/June 139
  - heterotransplantation of cell lines (in mice), May/June 140-141
  - prevention, May/June 159-163
  - animal studies, May/June 160-161
  - antiestrogens (see Antiestrogens)
  - clinical concepts in, May/June 161-163
  - proposals, current, May/June 161-163
  - tamoxifen in (see below)
- Breast cancer, tamoxifen in, May/June 133-176
  - abstract, May/June 134-136

Breast cancer (*cont.*)

- adjuvant, May/June 138-148
  - concepts, May/June 138-141
  - evolution of current practice, May/June 141-148
  - extended, May/June 147-148
  - in postmenopausal women, May/June 145-146
  - trials of, clinical, May/June 145
- antiestrogens (*see* Antiestrogens)
- chemotherapy plus, May/June 142-145
- endocrine replacement, May/June 158
- failure, May/June 148-151
- growth stimulated by tamoxifen, May/June 150
- long-term, May/June 151-158
  - estrogenic effects, May/June 155-157
  - liver carcinogenesis, May/June 157-158
  - ophthalmic effects, May/June 153
  - ovaries stimulating, May/June 151-152
  - teratogenesis, May/June 152-153
- maintenance, May/June 158
  - reduction of second primary cancers, May/June 158
- metabolites in patient serum, May/June 149
- prevention of breast cancer, efficacy, May/June 162
- Stockholm trial design, May/June 145

C

- c-kit ligand, July/Aug. 225-228
  - expression of, schematic representation, July/Aug. 227
- c-myc expression: deregulation of, Sept./Oct. 274-275
- CA-125: in ovarian cancer, Mar./Apr. 76-77
- Cancer
  - breast (*see* Breast cancer)
  - ovarian (*see* Ovarian cancer)

pain (*see* Pain of cancer)

- Carboplatin
  - aquation hydrolysis of, Mar./Apr. 90
  - in ovarian cancer, Mar./Apr. 89-93
- Carcinoembryonic antigen in colorectal carcinoma
  - as immunotherapy target, Sept./Oct. 306-307
  - prognosis, Sept./Oct. 304-305
  - progression, Sept./Oct. 303-307
- Carcinogenesis
  - liver, tamoxifen and, long-term, May/June 157-158
  - tamoxifen and, long-term, May/June 157-158
- Carcinoma
  - breast (*see* Breast carcinoma)
  - colorectal (*see* Colorectal carcinoma)
  - ovaries, staging, Jan./Feb. 15
- Carcinomatosis: abdominal, with normal ovaries, Mar./Apr. 117
- Care, supportive, in oncology, Nov./Dec. 335-405
  - abstract, Nov./Dec. 335-336
- CD44: in colorectal carcinoma progression, Sept./Oct. 293-294
- CEA (*see* Carcinoembryonic antigen)
- Celiac plexus ablation: in cancer pain control, Nov./Dec. 363-364
- Cell
  - DA, interleukin for, July/Aug. 228
  - progenitor, erythroid burst from, July/Aug. 188
  - stem, types of, Jan./Feb. 21
  - stem cell factor, July/Aug. 225-228
  - stem (*see* Stem cell)
- CFU
  - E, July/Aug. 185
  - Eo, July/Aug. 186
  - GM, July/Aug. 185, July/Aug. 187
  - progenitor cell colony, July/Aug. 186
  - Mega, July/Aug. 185-186

- Chemotherapy  
 combination, as adjuvant in  
   breast cancer, May/June 142  
   of germ cell tumors, Mar./Apr. 115  
   of ovarian cancer (see Ovarian  
     cancer chemotherapy)  
   with tamoxifen in breast cancer,  
     May/June 142-145
- Chondroitin sulfate proteoglycan: in  
 colorectal carcinoma prognosis,  
 Sept./Oct. 289
- Cisplatin  
 aquation hydrolysis of, Mar./Apr. 90  
 in ovarian cancer, Mar./Apr. 88-  
 89, 107, 108
- Coanalgesics  
 in pain of cancer, Nov./Dec. 349-  
 352  
 recommended, Nov./Dec. 350
- Cognitive behavioral therapy: and  
 pain of cancer, Nov./Dec. 353
- Collagen type IV: in colorectal carci-  
 noma prognosis, Sept./Oct.  
 288-289
- Collagenase: type IV in colorectal  
 carcinoma progression, Sept./  
 Oct. 294-295
- Colon, tumorigenesis  
 genetic alterations in, Sept./Oct.  
 268-275  
 molecular alterations in, second-  
 ary, Sept./Oct. 268-275
- Colorectal carcinoma, Sept./Oct.  
 265-328  
 abstract, Sept./Oct. 265  
 biology of, Sept./Oct. 265-328  
 carcinoembryonic antigen in (see  
   Carcinoembryonic antigen in  
     colorectal carcinoma)  
 hyperplasia in, Sept./Oct. 269-272  
 immunotherapy target, carcino-  
 embryonic antigen as, Sept./  
 Oct. 306-307  
 prognosis  
   basement membrane in, Sept./  
   Oct. 286-287  
   carcinoembryonic antigen in,  
   Sept./Oct. 304-305  
   chondroitin sulfate proteogly-  
   can in, Sept./Oct. 289  
   collagen type IV in, Sept./Oct.  
   288-289  
   fibronectin in, Sept./Oct. 290  
   laminin in, Sept./Oct. 288  
 progression, Sept./Oct. 281-307  
 of adenoma to carcinoma in  
   situ, molecular events in,  
   Sept./Oct. 275-280  
 biology of, Sept./Oct. 281-283  
 biology of, clinical, Sept./Oct.  
 283-284  
 carcinoembryonic antigen in,  
 Sept./Oct. 303-307  
 CD44 in, Sept./Oct. 293-294  
 collagenase in, type IV, Sept./  
 Oct. 294-295  
 DCC in, Sept./Oct. 276, Sept./  
 Oct. 293-294  
 glycosylation alteration, Sept./  
 Oct. 302-303  
 implantation of tumor, mole-  
 cules involved in, Sept./Oct.  
 298-299  
 integrins in, Sept./Oct. 290-292  
 laminin-binding proteins in,  
 nonintegrin, Sept./Oct. 292  
 lectins in, Sept./Oct. 292-293  
 MCC in, Sept./Oct. 275-276  
 to metastases, events during,  
 Sept./Oct. 270  
 metastasis suppressor gene  
 changes in, Sept./Oct. 297-  
 298  
 mucins in, Sept./Oct. 299-303  
 mucins in, ectopic peptide pro-  
 duction, Sept./Oct. 301-302  
 mucins in, organ-specific, loss  
 of, Sept./Oct. 300  
 multiple tasks for neoplastic  
 cell to establish a metastasis,  
 Sept./Oct. 282  
 neovascularization in, Sept./Oct.  
 297  
 p53 function loss in, Sept./Oct.  
 277-278  
 prognostic factors, Sept./Oct.  
 285  
 prognostic variables, Sept./Oct.  
 285-290  
 proteases in, Sept./Oct. 294-299

Colorectal carcinoma (*cont.*)  
 proteases in, inhibitors, Sept./Oct.  
 296-297  
 proto-oncogene changes in, Sept./  
 Oct. 297-298  
*ras* genes in, Sept./Oct. 276-277  
 receptors for attachment to cells,  
 basement membrane and  
 matrix molecules, Sept./Oct.  
 290-294  
 summary, Sept./Oct. 307  
 tyrosine kinase activation in,  
 Sept./Oct. 278-280  
 urokinase in, Sept./Oct. 295-  
 296  
 transformation, Sept./Oct. 267-  
 281  
 adenoma development, Sept./  
 Oct. 272-273  
*c-myc* expression deregulation,  
 Sept./Oct. 274-275  
 events in colorectal epithelial  
 cells, Sept./Oct. 270  
 polyposis syndrome, familial  
 adenomatous, in APC gene,  
 Sept./Oct. 273-274  
 summary, Sept./Oct. 280-281  
 Colorectal epithelial cells: events  
 during malignant transforma-  
 tion and progression to me-  
 tastases, Sept./Oct. 270  
 Constipation  
 management, Nov./Dec. 347  
 with opioid analgesics, Nov./Dec.  
 346-349  
 Cordotomy: percutaneous, in can-  
 cer pain control, Nov./Dec.  
 358-360  
 Cyclophosphamide: in ovarian can-  
 cer, Mar./Apr. 91, Mar./Apr.  
 107  
 Cyst: ovarian epithelial, surface in-  
 clusion, Jan./Feb. 16  
 Cytogenetics: in ovarian cancer,  
 Jan./Feb. 25-27  
 Cytokines  
 hematopoietic activity of, July/  
 Aug. 191  
 and hematopoietic growth fac-  
 tors, July/Aug. 191

Cytometry: flow studies, in ovarian  
 cancer, Mar./Apr. 82-83  
 Cyto-reductive surgery: in ovarian  
 cancer, Mar./Apr. 79-80

## D

DA cells: interleukin for, July/Aug.  
 228  
 DCC: in colorectal carcinoma pro-  
 gression, Sept./Oct. 276, Sept./  
 Oct. 293-294  
 Depression: and pain of cancer,  
 Nov./Dec. 387  
 Diarrhea: in supportive care in can-  
 cer, Nov./Dec. 370  
 Dimethylbenzanthracene: breast  
 carcinoma due to (in rat),  
 May/June 139-140  
 DNA  
 -platinum adduct levels in ovar-  
 ian cancer prognosis, Mar./  
 Apr. 84-85  
 repair and drug resistance in  
 ovarian cancer, Jan./Feb.  
 43-44  
 Drug resistance in ovarian cancer  
 (see Ovarian cancer, drug  
 resistance in)

## E

Endocrine: replacement in tamox-  
 ifen in breast cancer, May/  
 June 158  
 Enteral nutrition: in supportive care  
 in cancer, Nov./Dec. 373-376  
 Epidural steroids: in cancer pain  
 control, Nov./Dec. 365-366  
 Epithelium of ovaries (see Ovaries,  
 epithelium)  
 Erythroid burst: from single progen-  
 itor cell, July/Aug. 188  
 Erythropoietin, July/Aug. 192-196  
 Esophagus: sore, in supportive care  
 in cancer, Nov./Dec. 370  
 Estrogens  
 effects of tamoxifen on, May/June  
 155-157  
 metabolism, May/June 148-150

## F

- Family-centered care: best model for successful coping with cancer, Nov./Dec. 384-385  
Fibronectin: in colorectal carcinoma prognosis, Sept./Oct. 290  
Flow cytometric studies: in ovarian cancer, Mar./Apr. 82-83

## G

### G-CSF

- modulation of adhesion molecules on neutrophils by, July/Aug. 236

- in vivo activities of, July/Aug. 235

### Gene

- amplification of Her-2-neu, in ovarian cancer survival, Mar./Apr. 84

- APC, and polyposis syndrome, familial adenomatous, Sept./Oct. 273-274

- ras, in colorectal carcinoma progression, Sept./Oct. 276-277

- Genetic alterations: in colon tumorigenesis, Sept./Oct. 268-275

- Genetic events: in transformation and progression to metastases in colorectal epithelial cells, Sept./Oct. 270

- Genetic factors: in ovarian cancer, Mar./Apr. 71-72

- Germ cell tumors of ovaries, Mar./Apr. 114

- chemotherapy, Mar./Apr. 115

- Glycosylation alteration: in colorectal carcinoma progression, Sept./Oct. 302-303

### GM-CSF

- high-affinity receptors for, July/Aug. 234

- modulation of adhesion molecules on neutrophils, July/Aug. 236

- in vivo activities of, July/Aug. 235

### Granulocyte

- colony-stimulating factor, July/Aug. 196-202

- macrophage colony-stimulating factor, July/Aug. 206-214

### Growth factors

- activation of signal transduction pathways, Jan./Feb. 13

- hematopoietic (see Hematopoietic growth factors)

- regulation of ovarian cancer, Jan./Feb. 31-34

- tamoxifen stimulating, May/June 150

## H

### Hematopoiesis

- hierarchical organization, schematic summary, July/Aug. 184

- historical background, July/Aug. 182-191

- negative regulators of, July/Aug. 230-232

- scientific background, July/Aug. 182-191

- Hematopoietic activity: of cytokines, July/Aug. 191

- Hematopoietic growth factors, July/Aug. 181-259

- abstract, July/Aug. 181-182

- antagonists of, July/Aug. 231-232

- biologic activities of, multiple, July/Aug. 190

- biology of, summary overview, July/Aug. 233-239

- combinations of, July/Aug. 229-230

- cytokines and, July/Aug. 191

- effects of, stimulatory, withdrawal of, July/Aug. 231

- individual specific, introduction to, July/Aug. 191-230

- mediating mobilization of hematopoietic progenitor cells into circulation, July/Aug. 238

- multilineage, July/Aug. 206-228

- myeloid, toxicities of, July/Aug. 213

- receptors of, July/Aug. 232-233

- single-lineage, July/Aug. 192-206

Hematopoietic growth factors

(cont.)

therapeutic potential, summary overview, July/Aug. 233-239

Hematopoietic stimuli: and specific blood cells, July/Aug. 192

Her-2-neu gene amplification: in ovarian cancer survival, Mar./Apr. 84

Hexamethylmelamine: in ovarian cancer, Mar./Apr. 94-95

HILDA, July/Aug. 228

Host-tumor microenvironment, Sept./Oct. 287

Hyperplasia: in colorectal carcinoma, Sept./Oct. 269-272

Hypertonic saline: in cancer pain control, Nov./Dec. 365-366

Hypogastric plexus ablation: in cancer pain control, Nov./Dec. 364

I

Ifosfamide: in ovarian cancer, Mar./Apr. 96

IL

1, July/Aug. 222-224

2, July/Aug. 204-205

3, July/Aug. 215-220  
high-affinity receptors for, July/Aug. 234

4, July/Aug. 220-222

5, July/Aug. 205-206  
high-affinity receptors for, July/Aug. 234

6, July/Aug. 224-225  
historical nomenclature for, summary of, July/Aug. 224

7, July/Aug. 206

8, July/Aug. 230

9, July/Aug. 228

10, July/Aug. 230-231

11, July/Aug. 228

12, July/Aug. 206

for DA cells, July/Aug. 228

Immunotherapy target: carcinoembryonic antigen as, in colorectal carcinoma, Sept./Oct. 306-307

Integrins: in colorectal carcinoma progression, Sept./Oct. 290-292

Interleukin (see IL)

L

Laminin

binding proteins, nonintegrin, in colorectal carcinoma progression, Sept./Oct. 292

in colorectal carcinoma prognosis, Sept./Oct. 288

Lectins: in colorectal carcinoma progression, Sept./Oct. 292-293

Leukemia inhibitory factor, July/Aug. 228

LIF, July/Aug. 228

M

M-CSF binding: to cell surface receptors, July/Aug. 203

Macrophage colony-stimulating factor, July/Aug. 202-204

MCC: in colorectal carcinoma progression, Sept./Oct. 275-276

Melphalan: in ovarian cancer, Mar./Apr. 87

Mental health professionals: and pain of cancer, Nov./Dec. 388-389

Metastases

colorectal epithelial cell events during malignant transformation and progression, Sept./Oct. 270

multiple tasks of neoplastic cell to establish, Sept./Oct. 282

in rectal adenocarcinoma, Sept./Oct. 286

suppressor gene changes in colorectal carcinoma progression, Sept./Oct. 297-298

Model

in binding of M-CSF to cell surface receptors, July/Aug. 203  
of drug resistance (see Ovarian cancer, drug resistance models)

Molecular alterations: secondary, in colon tumorigenesis, Sept/Oct. 268-275

Morphine: in cancer pain control, Nov/Dec. 360

#### Mouth

dry, in supportive care in cancer, Nov/Dec. 370

sore, in supportive care in cancer, Nov/Dec. 370

Mucins in colorectal carcinoma progression (*see* Colorectal carcinoma progression, mucins in)

Myeloid hematopoietic growth factors: toxicities of, July/Aug. 213

## N

N-nitrosomethylurea: causing breast carcinoma (in rat), May/June 140

NAP-1, July/Aug. 230

Nausea control, Nov/Dec. 348  
with opioid analgesics, Nov/Dec. 346-349

Neovascularization: in colorectal carcinoma progression, Sept/Oct. 297

Neurolysis: spinal, in cancer pain control, Nov/Dec. 364-365

#### Neutrophils

G-CSF and, July/Aug. 236

GM-CSF and, July/Aug. 236

N-Nitrosomethylurea: causing breast carcinoma (in rat), May/June 140

Nonsteroidal antiinflammatory drugs: in pain of cancer, Nov/Dec. 349-352

Nutrient requirements: determination of, and supportive care in cancer, Nov/Dec. 401-402

#### Nutrition

crash course, Nov/Dec. 401-403

history in, Nov/Dec. 401

laboratory, Nov/Dec. 401

monitoring supplemented patient, Nov/Dec. 403

nonprotein calorie-to-nitrogen ratio, Nov/Dec. 403

nutrient sources, Nov/Dec. 402  
physical exam before, Nov/Dec. 401

requirements by clinical status, Nov/Dec. 403

Nutrition in supportive care in cancer, Nov/Dec. 368-378

assessment, Nov/Dec. 368

clinic, prototypical, essential features of, Nov/Dec. 369

enteral, Nov/Dec. 373-376

palliative care setting, Nov/Dec. 378

parenteral, Nov/Dec. 376-378

poor appetite, Nov/Dec. 370  
support

options, Nov/Dec. 369-378

oral, Nov/Dec. 369-373

weight loss, Nov/Dec. 370

## O

Oncology, supportive care in, Nov/Dec. 335-405

abstract, Nov/Dec. 335-336

Ophthalmic effects: of long-term tamoxifen, May/June 153

#### Opioid analgesics

administration, alternative routes, Nov/Dec. 344

constipation after, Nov/Dec. 346-349

doses, equianalgesic, Nov/Dec. 340

nausea after, Nov/Dec. 346-349

pain prevention, around-the-clock, Nov/Dec. 338-346

side effects, adverse, Nov/Dec. 346

prevention of, Nov/Dec. 346-349

therapy, recommended, Nov/Dec. 341

Osteoporosis: after tamoxifen, May/June 154

Ovarian cancer, Jan/Feb. 5-57,  
Mar/Apr. 69-125

abstract, Mar/Apr. 67-68

Ovarian cancer (*cont.*)

- Adriamycin in, Mar/Apr. 93  
biology, Jan./Feb. 5-57  
abstract, Jan./Feb. 5-57  
CA-125 in, Mar/Apr. 76-77  
carboplatin in, Mar/Apr. 89-93  
chemotherapy  
advanced cancer, Mar/Apr.  
87-98  
agents, listing of, Mar/Apr. 88  
combination, Mar/Apr. 98-99  
high-dose experimental, Mar/  
Apr. 106-109  
intraperitoneal, Mar/Apr. 99-  
101  
postoperative, Mar/Apr. 114-  
116  
regimens, new, Mar/Apr. 98  
single nonplatinum drug vs.  
nonplatinum combinations,  
Mar/Apr. 88  
survival curves with, Mar/Apr.  
94  
cisplatin in, Mar/Apr. 107, 108  
classification, histologic, Mar/Apr.  
73  
cyclophosphamide in, Mar/Apr.  
91, Mar/Apr. 107  
cytogenetics in, Jan./Feb. 25-27  
cytoreductive surgery in, Mar/  
Apr. 79-80  
development, Jan./Feb. 7-36  
diagnosis, Mar/Apr. 73-75  
drug resistance, Jan./Feb. 36-44  
DNA repair in, Jan./Feb. 43-44  
drug levels, Jan./Feb. 40-41  
mechanisms, Jan./Feb. 40-44  
mechanisms, classes of, Jan/  
Feb. 41  
models, Jan./Feb. 37-39  
models, in vitro, Jan./Feb.  
37-38  
models, in vivo, Jan./Feb. 38-39  
models, tumor biopsy material,  
Jan./Feb. 37  
reversal, Mar/Apr. 110-112  
reversal, trials in progress or  
planned, Mar/Apr. 110  
sulfhydryl molecules in, Jan/  
Feb. 42-43  
epidemiology, Mar/Apr. 69-71  
etiology, Jan./Feb. 18-22  
genetic factors in, Mar/Apr.  
71-72  
grade, Jan./Feb. 14-18  
histologic, Jan./Feb. 17  
in prognosis, Mar/Apr. 81-82  
growth regulation of, Jan./Feb.  
31-34  
heterozygosity loss in, Jan./Feb.  
28-29  
hexamethylmelamine in, Mar/  
Apr. 94-95  
ifosfamide in, Mar/Apr. 96  
malignant transformation, Jan/  
Feb. 14-36  
spontaneous (in rat), Jan./Feb.  
22  
markers of, Jan./Feb. 34-35  
melphalan in, Mar/Apr. 87  
molecular basis, insights into,  
Jan./Feb. 22-30  
pathology, Mar/Apr. 72-73  
in prognosis, Mar/Apr. 83  
polymorphism in, restriction frag-  
ment length, Jan./Feb. 27-30  
principle of, Jan./Feb. 26  
prognosis, Mar/Apr. 80-85  
age in, Mar/Apr. 82  
cytometric studies in, flow,  
Mar/Apr. 82-83  
histologic subtype in, Mar/Apr.  
81-82  
limited cancer, Mar/Apr. 86  
oncogene abnormalities in,  
Mar/Apr. 83  
performance status in, Mar/  
Apr. 82  
platinum-DNA adduct levels in,  
Mar/Apr. 84-85  
residual disease volume in,  
Mar/Apr. 82  
radiotherapy, Mar/Apr. 101-103  
recurrent, treatment, Mar/Apr.  
105-106  
remission, clinical complete,  
management, Mar/Apr. 103-  
105  
risk factors for, Mar/Apr. 70  
screening for, Mar/Apr. 75-77

stage, Jan./Feb. 14-18, Mar./Apr. 77-79

FIGO system, Mar./Apr. 78

in prognosis, Mar./Apr. 81

survival

advanced cancer, Mar./Apr. 107

in chemotherapy, Mar./Apr. 94  
curves based on Her-2-neu  
gene amplification, Mar./Apr. 84

in early stage cancer, Mar./Apr. 87

taxol in, Mar./Apr. 96-98

treatment

approaches based on disease  
biology, Jan./Feb. 35-36

experimental, Mar./Apr. 106-112

invasive early stage, Mar./Apr. 85-87

potential, for prevention or recurrence delay, Mar./Apr. 105  
recurrent cancer, Mar./Apr. 105-106

ultrasound in, Mar./Apr. 76

Ovaries

cancer (*see* Ovarian cancer)

carcinoma staging, Jan./Feb. 15

cyst, inclusion, Jan./Feb. 16

epithelium, surface

cell inclusion cyst formation,  
Jan./Feb. 16

features, Jan./Feb. 7-9

function, Jan./Feb. 7-9

malignant transformation, Jan./Feb. 14-36

malignant transformation,  
spontaneous (in rat), Jan./Feb. 22

normal, Jan./Feb. 7-13

regulation, Jan./Feb. 9-12

tamoxifen stimulating, May/June 151-152

tumors

borderline, Mar./Apr. 112-113  
classification, Jan./Feb. 8

epithelial, prognostic factors,  
Mar./Apr. 80-81

germ cell, Mar./Apr. 114

germ cell, chemotherapy, Mar./Apr. 115

nonepithelial, treatment, Mar./Apr. 114-116

## P

p53: function loss in colorectal carcinoma progression, Sept./Oct. 277-278

Pain of cancer

addiction with control, fears of,  
Nov./Dec. 349

behavioral therapy in, cognitive,  
Nov./Dec. 353

breakthrough, as-needed supplements for, Nov./Dec. 338-346

celiac plexus ablation in, Nov./Dec. 363-364

coanalgesics in, Nov./Dec. 349-352

cordotomy in, percutaneous,  
Nov./Dec. 358-360

depression and, Nov./Dec. 387

diagnose origin of each pain and  
initiate specific treatment,  
Nov./Dec. 337-338

hypertonic saline in, Nov./Dec. 365-366

hypogastric plexus ablation in,  
Nov./Dec. 364

management, comprehensive,  
Nov./Dec. 337-354

mental health professionals and,  
Nov./Dec. 388-389

neurolysis in, spinal, Nov./Dec. 364-365

pain-blocking procedures, local  
and regional, integrated into  
interdisciplinary pain management program, Nov./Dec. 353

procedure-oriented control, Nov./Dec. 354-368

contraindications, Nov./Dec. 355-357

indications, Nov./Dec. 355-357

listing of procedures, Nov./Dec. 355

techniques, Nov./Dec. 357-358

**Pain of cancer (cont.)**

- steroids in, epidural, Nov/Dec. 365-366
- syndromes, common, Nov/Dec. 338
- tolerance with control of, fears of, Nov/Dec. 349
- Parenteral nutrition: in supportive care in cancer, Nov/Dec. 376-378
- Physician: awareness and management of personal stress in cancer, Nov/Dec. 389-391
- Platinum-DNA adduct levels: in ovarian cancer prognosis, Mar./Apr. 84-85
- Polymorphism, restriction fragment length
  - in ovarian cancer, Jan./Feb. 27-30
  - principle of, Jan./Feb. 26
- Polyposis syndrome: familial adenomatous, and APC gene, Sept./Oct. 273-274
- Progenitor cell: erythroid burst from, July/Aug. 188
- Proteases
  - in colorectal carcinoma progression, Sept./Oct. 294-299
  - inhibitors in colorectal carcinoma progression, Sept./Oct. 296-297
- Proto-oncogenes: changes in colorectal carcinoma progression, Sept./Oct. 297-298
- Psychosocial
  - adaptation in supportive care in cancer, Nov/Dec. 382-384
  - collaborating with mental health professionals, Nov/Dec. 388-389
  - crisis situations, Nov/Dec. 387-388
  - differentiating between individual and group services, Nov/Dec. 386
  - establishing trust with family from outset, Nov/Dec. 384-385

- family-centered care best model for successful coping, Nov/Dec. 384-385
- guidance regarding high-risk family subsets, Nov/Dec. 385
- individualizing information, Nov/Dec. 383
- informational needs changing, Nov/Dec. 383-384
- inquiring about other sources of stress, Nov/Dec. 388
- overload allowed for, Nov/Dec. 383
- physician-patient communication in, Nov/Dec. 382-384
- setting limits on unrealistic expectations, Nov/Dec. 390
- supportive services strengthening physician/patient/family triad, Nov/Dec. 386-389
- distress prevention in supportive care in cancer, Nov/Dec. 379-391
- physician acknowledges crisis, Nov/Dec. 381
- physician discusses philosophy of cancer, Nov/Dec. 381-382
- physician explains hospital and office structure, Nov/Dec. 382
- physician's opportunity, Nov/Dec. 379-391
- physician's use of structure creating security and trust, Nov/Dec. 380-382
- intervention for physicians, principles for supportive care in cancer, Nov/Dec. 380

**R**

- Radiotherapy: of ovarian cancer, Mar./Apr. 101-103
- ras gene: in colorectal carcinoma progression, Sept./Oct. 276-277
- Rectum
  - adenocarcinoma, invasion and metastases, Sept./Oct. 286
  - colorectal carcinoma (*see* Colorectal carcinoma)

## S

- Saline: hypertonic, in cancer pain control, Nov./Dec. 365-366
- Sertoli-Leydig tumors, Mar./Apr. 117
- Sex cord-stromal tumors, Mar./Apr. 116-117
- Spine
  - analgesia in cancer pain control, Nov./Dec. 360-364
  - neurolysis in cancer pain control, Nov./Dec. 364-365
- Steel factor, July/Aug. 225-228
- Stem cell
  - factor, July/Aug. 225-228
  - types, Jan./Feb. 21
- Steroids
  - epidural, in cancer pain control, Nov./Dec. 365-366
  - in pain of cancer, Nov./Dec. 349-352
- Stress, personal
  - in cancer, physician's awareness and management of, Nov./Dec. 389-391
  - response to, and supportive care in cancer, Nov./Dec. 390
- Stromal-sex cord tumors, Mar./Apr. 116-117
- Sulfhydryl molecules: in drug resistance in ovarian cancer, Jan./Feb. 42-43
- Supportive care in oncology, Nov./Dec. 335-405
  - abstract, Nov./Dec. 335-336

## T

- Tamoxifen
  - atherosclerosis after, May/June 154-155
  - in breast cancer (see Breast cancer, tamoxifen in)
  - osteoporosis after, May/June 154
  - thromboembolic disorders after, May/June 155
  - uterine stimulation by, May/June 156-157

## Taxol

- GOG trial of, Mar./Apr. 97
- in ovarian cancer, Mar./Apr. 96-98
- structure, Mar./Apr. 97
- Teratogenesis: of tamoxifen, May/June 152-153
- TGF-beta, July/Aug. 231
- Thromboembolic disorders: after tamoxifen, May/June 155
- TNF-alpha, July/Aug. 231
- Tolerance: fears of, with pain of cancer treatment, Nov./Dec. 349
- Toxicity: of myeloid hematopoietic growth factors, July/Aug. 213
- Transplantation: heterotransplant of breast cancer cell lines (in mice), May/June 140-141
- Tumor
  - host microenvironment, Sept./Oct. 287
  - ovaries (see Ovaries, tumors)
  - Sertoli-Leydig, Mar./Apr. 117
  - sex cord-stromal, Mar./Apr. 116-117
- Tumorigenesis, colon (see Colon, tumorigenesis)
- Tyrosine kinases: activation in colorectal carcinoma progression, Sept./Oct. 278-280

## U

- Ultrasound: in ovarian cancer, Mar./Apr. 76
- Urokinase: in colorectal carcinoma progression, Sept./Oct. 295-296
- Uterus: stimulation by tamoxifen, May/June 156-157

## W

- Weight loss
  - supportive care in cancer and, Nov./Dec. 370
  - time course of, evaluation of, in cancer, Nov./Dec. 368